LTS Lohmann Therapie-Systeme AG

Andernach, October 1, 2026 - LTS Lohmann Therapie-Systeme AG (LTS) today officially opened its new innovation center, InnoVerse, at the company's site in Andernach, Germany. Following three years of construction and an investment of approximately EUR 40 m

LTS today celebrated the groundbreaking of a major expansion project at its West St. Paul, Minnesota campus. Source

Nasal spray repurposing through the 505(b)(2) regulatory pathway has emerged as a compelling approach, offering a unique opportunity to breathe new life into existing drugs and improve patient experiences. Bringing a new drug to market is a complex and co

OTFs are well established as an important non-invasive route for drug administration. Placed on or under the tongue or buccally, they are absorbed by the oral mucosa with the active substance directly transported into the bloodstream. Source

It is only in true market leader organisations that pure innovation is encouraged, with experts devoting time to genuine research alongside their operational responsibilities. Source

LTS Lohmann Therapie-Systeme AG has once again been named a Best Managed Company, marking the third consecutive year the company has received this prestigious recognition. Source

Because nasal sprays are defined as combination products, it can be tempting to think of them separately in terms of drug product and device, however, these cannot be considered as separate elements in this context.Indeed, it is crucial that both drug pro

LTS has joined the Responsible Care Initiative of the International Council of Chemical Associations (ICCA). Source

LTS announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions. Source